SCHEMBL498164

SCHEMBL498164

CCCCOc1cc(CN(C)c2ccc(O[Si](C)(C)C(C)(C)C)cc2C)ccc1C(=O)OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 2/20 0.36
THRB P10828 2/20 0.36
PPARG P37231 2/20 0.36
PPARA Q07869 2/20 0.36
NR1H2 P55055 1/20 0.36
PPARD Q03181 1/20 0.36
NR1H3 Q13133 1/20 0.36
DRD2 P14416 1/20 0.35
HTT P42858 2/20 0.34
ALDH1A1 P00352 2/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
PLA2G2A P14555 2/20 0.34
MMP9 P14780 2/20 0.34
MMP13 P45452 2/20 0.34
ADAM17 P78536 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MMP1 P03956 1/20 0.34
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL498136 0.88 NPC1 (0.35) DRD2ALDH1A1NPC1RAB9ATSHR
SCHEMBL498879 0.83 CA12 (0.39) THRATHRBHTTALDH1A1SMN1; SMN2
SCHEMBL20046200 0.74 CA1 (0.43) HTTALDH1A1NPC1RAB9AGAA
SCHEMBL498587 0.73 TDP1 (0.47) PPARGPPARAHTTALDH1A1MAOA
SCHEMBL2772136 0.72 PPARA (0.44) PPARGPPARAPTPN1TP53
SCHEMBL2320471 0.71 DRD2 (0.46) DRD2HTTALDH1A1SMN1; SMN2GAA
SCHEMBL30007012 0.69 CA12 (0.43) NPC1RAB9AGAAKDM4EL3MBTL1
SCHEMBL2201771 0.69 CA12 (0.43) NPC1RAB9AGAAKDM4EL3MBTL1
SCHEMBL497755 0.69 ALDH1A1 (0.50) PPARGPPARAHTTALDH1A1MAOA
SCHEMBL498135 0.68 KMT2A (0.36) PPARGPPARAPPARDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106077-B2 Compounds and methods for modulating FXR ELI LILLY AND COMPANY (US) 2012-01-31 US disclosed
US-7846960-B2 FXR agonists ELI LILLY AND COMPANY (US) 2010-12-07 US disclosed
EP-2029547-B1 FXR AGONISTS LILLY CO ELI (US) 2010-04-28 EP disclosed
EP-2029558-B1 COMPOUNDS AND METHODS FOR MODULATING FXR LILLY CO ELI (US) 2010-03-10 EP disclosed
US-20090270460-A1 FXR AGONISTS JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT 2009-10-29 US disclosed
US-20090093524-A1 COMPOUNDS AND METHODS FOR MODULATING FXR JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270460-A1 FXR AGONISTS NR1H4, SLC10A1, GPBAR1 THRA 285/4885THRB 146/4885PPARG 19/4885
US-20090093524-A1 COMPOUNDS AND METHODS FOR MODULATING FXR NR1H4, SLC10A1, FXR1 THRA 932/4885THRB 326/4885PPARG 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.